Navigation Links
EmSense Announces Release of Revolutionary EmBand 24(TM)
Date:3/22/2010

SAN FRANCISCO, March 22 /PRNewswire/ -- EmSense Corporation, the company that created the first scalable electroencephalography (EEG) brainwave measurement technology, today announced the addition of the EmBand 24™ to the EmBand™ family of neuromarketing measurement devices.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100322/AQ74210)

Using its Made for Purpose™ design, EmSense has employed several new proprietary technologies in the release of the new EmBand 24, including Sensor Fusion Processors™, Contact Clusters™ and Through the Hair EEG™.  The headset is designed specifically for market research and overcomes many limitations of using medical EEG for market research. 

"Now marketers can have more extensive, robust measurements without trading off consumer comfort, quantitative samples or ease of use," says Keith Winter, EmSense CEO.

EmSense proprietary sensors provide more targeted measurement with greater precision than medical sensors.  The Contact Cluster technology enables the ability to take individual anatomical differences into account and give maximum spatial resolution in targeted regions. New Through the Hair EEG sensors allow non-obtrusive measurement without the need for unpleasant, messy gels that require respondent clean-up. 

Using 24 EEG sensors, each measuring at 20,000 times per second, the headset collects 480,000 measurements per second.  In addition, the EmBand 24 provides an unparalleled signal-to-noise ratio in real-world, in-context conditions.  In keeping with the company's non-invasive design philosophy, the EmBand 24 headset does not require caps, gels or wires and calibrates in only one minute. 

"With the global availability of the EmBand 24," according to Chief Analytics Officer Elissa Moses, "the ability to objectively understand consumer engagement and emotional response will ultimately accelerate the success rate for ad campaigns, package restages and new product introductions."

The EmBand 24 affords clients increased measurement in the key decision center area of the frontal lobes, as well as added measurements such as visual attention from sensing additional areas of the brain.  The new EmBand 24 will primarily be utilized for in-context studies such as in-store shopper research and product innovation, while the current EmBand will continue to be used for advertising, concepts, media content, package testing, online marketing and web-site usability. 

About EmSense

EmSense is a leading-edge neuroscience company that applies advances in EEG and other neurometrics to provide clients with deep and reliable understanding of consumers' emotional and cognitive engagement with marketing stimuli. The company's quantitative metrics deliver breakthrough insights that facilitate the creation and optimization of advertising, concepts, packaging, media content, online marketing, web-site usability and both the live in-store and virtual store shopping experiences.  EmSense works directly with marketers and also partners with a variety of leading established market research firms including Dynamic Logic, Fifth Dimension, GfK North America, IRI, Millward Brown, Perception Research Services, Red Dot Square and TNS. EmSense provides expertise and advancements in emotion tracking, cognitive neuroscience, analytics, and market research through their proprietary EmBand and now EmBand 24, the first ever wireless, scalable, non-gel, non-invasive EEG neuroscience technology. The company is also the global leader in combining neurometrics with stationary and mobile eye tracking. EmSense Corporation is headquartered in San Francisco. To learn more about EmSense technology applications and neuroscience market research solutions, visit www.emsense.com.

SOURCE EmSense

Back to top

RELATED LINKS
http://www.emsense.com

'/>"/>

SOURCE EmSense
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):